<DOC>
	<DOCNO>NCT02372708</DOCNO>
	<brief_summary>To evaluate therapeutic efficacy safety treatment malignant melanoma combine semiantigen dinitrophenyl ( DNP ) situ immunotherapy laser therapy , carry monitor related immunological parameter patient . 72 patient stage III ( b c ) stage IV skin ( could excise operation ) malignant melanoma treat combine simple semiantigen DNP situ immunotherapy laser therapy respectively . The change peripheral blood CD4+CD25+Treg regulatory T cell ( Treg ) , CD8+T , CD4+ T effector cell , IL-10 , TGF-β inhibitory cytokine patient detect , change anti-DNP IgG antibody titer monitor , relationship delayed-type hypersensitivity ( DTH ) survival observe , result clinical follow-up also examine .</brief_summary>
	<brief_title>Clinical Research Treatments Advanced Malignant Melanoma Combining Situ Immunotherapy Laser Therapy</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>pathologically diagnose malignant melanoma , HMB45 ( +～++++ ) , S100 ( +～++++ ) ; Basically normal hepatic renal function well result blood routine examination ; Karnofsky score ≥ 60 ; Anticipated life span three month ; They malignant melanoma patient suffer skin malignant melanoma local distal metastasis unsuitable operation skin ; The therapeutic efficacy objectively evaluate reference criterion WHO ; All subject sign informed consent submit approve ethic committee hospital , compliance good followup easily carry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>